Resistell News:

Venturelab's series about Switzerland’s most inspiring entrepreneurs and founders continues with Danuta Cichocka, the co-founder and CEO of Resistell AG.

Venturelab's series about Switzerland’s most inspiring entrepreneurs and founders continues with Danuta Cichocka, the co-founder and CEO of Resistell AG.
Resistell News:

Venturelab's series about Switzerland’s most inspiring entrepreneurs and founders continues with Danuta Cichocka, the co-founder and CEO of Resistell AG.

The Muttenz-based biotech startup proposes an alternative to culture-based antibiograms, the current gold standard in antibiotic susceptibility testing. The EPFL spin-off offers a diagnostic device, the rapid AST method, which is based on the detection of movement caused by living bacterial cells. The new method reduces the time taken to get a result from days to minutes, shows which specific antibiotic is effective against the bacteria, and significantly improves the chances of patients’ survival.
Venturelab's series about Switzerland’s most inspiring entrepreneurs and founders continues with Danuta Cichocka, the co-founder and CEO of Resistell AG.
curves

Latest news

28th March 2019

Resistell selected as one of 10 Winners of Venture Leaders Life Sciences

Resistell was selected as one of ten new startups have been selected for Venture Leaders Life Sciences 2019. Chosen from among the most-promising life sciences startups in Switzerland, the team will embark on a packed, week-long roadshow in Boston. The startups will also pitch at the Startup Champions Seed Night event in Lausanne on 11 April.
25th March 2019

Join us at The Economist Antimicrobial Resistance Summit on 26.03.2019 in London

"Enough time has been wasted issuing warnings about antibiotic resistance. The moment has come to do something about it" ~The Economist
18th March 2019

The 50 Swiss startups in which to invest in 2019

Bilan selected Resistell as one of the Top 50 Swiss startups in which to invest in 2019! We are proud to be on the prestigious list with our rapid AST technology!
Resistell presented the science behind the rapid AST method during the AMR Berlin 2019 conference
18th March 2019

Resistell presented the science behind the rapid AST method during the AMR Berlin 2019 conference

We thank everyone who visited our scientific presentation in Berlin at Novel Antimicrobials & AMR Diagnostics Conference (14-15.03.2019). We are looking forward to all new future partnerships and collaborations!
Meet us it Berlin at Novel Antimicrobials and AMR Diagnostics 2019
13th March 2019

Meet us it Berlin at Novel Antimicrobials and AMR Diagnostics 2019

We invite you to meet us in Berlin at Novel Antimicrobials & AMR Diagnostics Conference (14-15.03.2019). For more details please visit https://amr-conference.com
Resistell wins 3rd stage of VentureKick
27th December 2018

Resistell wins 3rd stage of VentureKick

The jury of industry experts and investors selected Resistell to receive the highest level of Venture Kick’s financial support to bring their businesses to market.
12th December 2018

Resistell closes the seed financing round

Resistell has closed an oversubscribed seed financing round. Lead Investor Occident Group AG, Hemex AG and six other private investors invested in the EPFL spin-off developing the world’s fastest phenotypic antibiotic susceptibility test.
11th November 2018

Resistell a finalist of the Swiss Technology Award 2018!

Resistell AG a finalist of the Swiss Technology Award 2018!
Resistell wins the MassChallenge Switzerland 2018 Gold Award
1st November 2018

Resistell wins the MassChallenge Switzerland 2018 Gold Award

Resistell wins the MassChallenge Switzerland 2018 Gold Award
26th October 2018

Overuse of antibiotics 'risks return to dark ages of life-threatening surgery'

Warning comes as report shows 3 million common surgical procedures could be hazardous if infections become resistant to antibiotics
4th July 2018

Join us at the annual meeting of the SSM, 28-30 August.

Join us at the annual meeting of the Swiss Society for Microbiology held within the CHUV, Lausanne.
25th June 2018

Scientists Are Using a New Weapon to Fight Drug-Resistant Bacteria—Viruses

New treatments like phage therapy are being used to fight the deadly risk of antibiotic resistance, and Resistell is working to speed up and improve the identification of bacteria and the prescription of the correct medicines.
The Best Swiss Nanotechnology Startup 2018
11th June 2018

The Best Swiss Nanotechnology Startup 2018

We are please to share that on 07.06.2018 in Zurich, Resistell has received the Swiss Nanotechnology Startup Award for the Best Nanotechnology Startup 2018.
Resistell qualifies as a finalist of MassChallenge Switzerland 2018
6th June 2018

Resistell qualifies as a finalist of MassChallenge Switzerland 2018

Last week, we competed with over 200 startups from 31 countries in final judging round at Campus Biotech in Geneva. We are pleased to inform that Resistell AG qualified to the finals!